ASX Share rice
Tue 11 May 2021 - 06:08:pm (Sydney)

CDY Share Price

CELLMID LIMITEDCDYPharmaceuticals, Biotechnology & Life Sciences

CDY Company Information

Name:

Cellmid Limited

Sector:

Healthcare

Industry:

Biotechnology

GIC Industry:

Biotechnology

GIC Sub Industry:

Biotechnology

Address:

55 Clarence Street Sydney NSW Australia 2000

Phone:

61 2 9221 6830

CEO, MD & Exec. Director:

Ms. Maria Halasz

Managing Director of Advangen Inc:

Mr. Koichiro Koike

Group Financial Controller:

Mr. Matthew Dudek

Chief Operating Officer:

Mr. Dominic Burg

Head of R&D:

Dr. Graham Robertson

Global Head of Marketing Advangen Pty Ltd:

Ms. Trish Frelan

Company Sec.:

Mr. Lee Tamplin B.A.

Company Overview:

Cellmid Limited, a life sciences company, researches, develops, and commercializes diagnostic and therapeutic products for cancer and various chronic inflammatory conditions in Australia, the United States, and Japan. The company offers midkine, a driver and modulator of inflammatory diseases, including chronic inflammatory diseases and cancer; and focuses on blocking midkine, a protein for autoimmune disorders, chronic inflammation, osteoporosis, cardiovascular diseases, cancer, and neurodegenerative diseases. It also develops and sells over-the-counter products; and a range of FGF5 inhibitor hair growth products under the evolis, evolis Professional, Lexilis Hybrid, Jo-Ju RED, and Lexilis BLACK brands. In addition, the company sells SARS-CoV-2 antibody kits and PCR tests. It markets its products through retailers and wholesalers, as well as through a direct-to-consumer e-commerce platform. Cellmid Limited was incorporated in 2004 and is based in Sydney, Australia.

CDY Share Price Information

Shares Issued:

178.10M

Market Capitalisation:

$12.11M

Revenue (TTM):

$6.61M

Revenue Per Share (TTM):

$0.06

Earnings per Share:

$-0.078

Profit Margin:

-0.8924

Operating Margin (TTM):

$-0.88

Return On Assets (TTM):

$-0.33

Return On Equity (TTM):

$-0.83

Quarterly Revenue Growth (YOY):

-0.237

Gross Profit(TTM):

$4.95M

Diluted Earnings Per Share (TTM):

$-0.051

CDY CashFlow Statement

CashFlow Date:

2020-06-30

Change To Liabilities:

$424

Net Borrowings:

$-260,020

Net Income:

$-4,907,296

Total Cash From Operating Activities:

$-4,013,105

Depreciation:

$518.66K

Change To Inventory:

$-990,951

Change To Account Receivables:

$321.50K

Sale Purchase Of Stock:

$8.85M

Capital Expenditures:

$0

CDY Income Statement

Income Date:

2020-06-30

Income Before Tax:

$-4,817,820

Net Income:

$-4,907,300

Gross Profit:

$4.95M

Operating Income:

$-5,792,220

Other Operating Expenses:

$864.93K

Interest Expense:

$-19,750

Income Tax Expense:

$89.47K

Total Revenue:

$7.48M

Cost Of Revenue:

$2.53M

CDY Balance Sheet

Balance Sheet Date:

2020-06-30

Intangible Assets:

$1.76M

Total Liabilities:

$5.08M

Total Stockholder Equity:

$9.81M

Other Current Liabilities:

$1.93M

Total Assets:

$14.89M

Common Stock:

$56.06M

Other Current Assets:

$176.90K

Retained Earnings:

$-47,390,823

Other Liabilities:

$97.27K

Cash:

$6.97M

Total Current Liabilities:

$3.48M

Property - Plant & Equipment:

$1.50M

Net Tangible Assets:

$8.05M

Total Current Assets:

$11.63M

Long-Term Debt:

$1.03M

Net Receivables:

$1.87M

Short-Term Investments:

$3.26M

Inventory:

$2.61M

Accounts Payable:

$839.73K

Short-Term Investments:

$3.26

Non Current Liabilities Total:

$1.59M

CDY Share Price History

CDY News

29 Sep, 2020
This article will reflect on the compensation paid to Maria Halasz who has served as CEO of Cellmid Limited (ASX:CDY...